A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
AVENANCE - A Non-interventional Study to Provide Real-world Data on the Use of Avelumab as a Maintenance Treatment for Patients With Advanced or Metastatic Urothelial Carcinoma
A multicenter ambispective (retrospective and prospective) non-interventional study of patients with locally advanced or metastatic urothelial carcinoma (adv/mUC) treated with avelumab in France, not impacting the treatment decision made by the treating physician and the medical management of treated patients.
overall Survival from the start of the chemotherapy used in 1st line
Study Arms / Comparison Groups
Locally advanced or metastatic urothelial carcinoma patients treated with avelumab
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
July 13, 2021
June 30, 2024
Primary Completion Date
June 30, 2024
Inclusion Criteria: 1. Patient ≥ 18 years of age 2. Patient with locally advanced or metastatic urothelial carcinoma (irrespective of tumor histology) whose disease has not progressed (ongoing stable disease, partial response or complete response) following completion of first-line platinum-based chemotherapy and who has been (retrospective), is (retrospective and prospective), will be (prospective) treated with avelumab. - For a patient alive at the moment of the inclusion in the study : the patient must be informed of the study, he/she must be given an information letter signed by the investigator and must not be opposed to the collection of his/her data - For a patient who died before the inclusion in the study : the patient (during his life time) must not be opposed in writing to the collection of his data. 3. Patient benefiting from a social security scheme according to local regulations Exclusion Criteria: 4. For a patient alive at the moment of the inclusion in the study: patient without liberty, under tutelage, or unable to give oral consent. 5. Patient enrolled in a prospective interventional clinical trial assessing an investigational product.
18 Years - N/A
Accepts Healthy Volunteers
Pfizer CT.gov Call Center, 1-800-718-1021, [email protected]
Merck KGaA, Darmstadt, Germany
Pfizer CT.gov Call Center, Study Director, Pfizer